Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Diaxonhit    ALEHT   FR0013240934

DIAXONHIT (ALEHT)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 02/16 05:29:09 pm
4.555 EUR   +1.11%
 SummaryQuotesChartsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
4.5(c) 4.46(c) 4.485(c) 4.505(c) 4.555(c) Last
3 760 5 990 10 495 5 000 15 126 Volume
+0.22% -0.89% +0.56% +0.45% +1.11% Change
More quotes
Financials (€)
Sales 2017 48,3 M
EBIT 2017 -3,40 M
Net income 2017 -4,80 M
Debt 2017 2,80 M
Yield 2017 -
Sales 2018 50,9 M
EBIT 2018 0,90 M
Net income 2018 -1,20 M
Debt 2018 1,40 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0,97x
EV / Sales2018 0,89x
Capitalization 44,1 M
More Financials
Company
Diaxonhit engages in the research and commercialization of diagnostic products.Its portfolio consists of proprietary diagnostic products in the following areas: transplantation, infectious diseases and cancer diagnosis.The company markets Tetanus Quick Stick used for the evaluation of patient's... 
More about the company
Latest news on DIAXONHIT

- No features available -

More news
Sector news : Biotechnology & Medical Research - NEC
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02/13'Nothing is inevitable in sports. There’s a reason we play the games.' ... A ..
5
01/19When China rules the world. My review of Martin Jacques' book
3
01/19My reviews of two China-related books: Martin Jacques: https://t.co/reLhyyYTw.. 
01/18My latest post: The aloofness of Pax Sinica (on Martin Jacques book)
3
01/17My review of Martin Jacques' "When China rules the world".
31
More tweets
Qtime:80
Chart DIAXONHIT
Duration : Period :
Diaxonhit Technical Analysis Chart | ALEHT | FR0013240934 | 4-Traders
Technical analysis trends DIAXONHIT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 6,50 €
Spread / Average Target 43%
EPS Revisions
Managers
NameTitle
Jean-Michel Carle Chairman-Management Board
Jean-Pierre Hermet Chairman-Supervisory Board
Hervé Duchesne de Lamotte Chief Financial Officer
Michel Picot Member-Supervisory Board
Danièle Guyot-Caparros Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
DIAXONHIT-4.56%55
CELLTRION, INC.--.--%36 110
IQVIA HOLDINGS INC6.93%21 125
LONZA GROUP-7.82%18 606
INCYTE CORPORATION-6.91%18 063
NEKTAR THERAPEUTICS40.66%13 227